NO20015298D0 - Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne - Google Patents
Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerneInfo
- Publication number
- NO20015298D0 NO20015298D0 NO20015298A NO20015298A NO20015298D0 NO 20015298 D0 NO20015298 D0 NO 20015298D0 NO 20015298 A NO20015298 A NO 20015298A NO 20015298 A NO20015298 A NO 20015298A NO 20015298 D0 NO20015298 D0 NO 20015298D0
- Authority
- NO
- Norway
- Prior art keywords
- glp
- ischemic
- improve
- function
- biologically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/303,016 US6429197B1 (en) | 1998-10-08 | 1999-04-30 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
PCT/US2000/011652 WO2000066142A2 (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20015298D0 true NO20015298D0 (no) | 2001-10-29 |
NO20015298L NO20015298L (no) | 2001-12-28 |
Family
ID=23170209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015298A NO20015298L (no) | 1999-04-30 | 2001-10-29 | Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne |
Country Status (14)
Country | Link |
---|---|
US (2) | US6429197B1 (no) |
EP (1) | EP1187628B1 (no) |
JP (1) | JP2002543145A (no) |
CN (1) | CN1376072A (no) |
AT (1) | ATE369873T1 (no) |
AU (2) | AU774084B2 (no) |
CA (1) | CA2368772C (no) |
DE (1) | DE60035987T2 (no) |
ES (1) | ES2290029T3 (no) |
IL (1) | IL145829A0 (no) |
MX (1) | MXPA01010937A (no) |
NO (1) | NO20015298L (no) |
NZ (1) | NZ514609A (no) |
WO (1) | WO2000066142A2 (no) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138486B2 (en) * | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20060160740A1 (en) * | 1999-10-21 | 2006-07-20 | Suad Efendic | Use of GLP-1 or analogs in treatment of stroke |
ES2307619T3 (es) | 2000-05-19 | 2008-12-01 | Amylin Pharmaceuticals, Inc. | Tratamiento del sindrome coronario agudo con glp-1. |
CZ304002B6 (cs) * | 2000-06-16 | 2013-08-14 | Eli Lilly And Company | Analogy peptidu-1 podobného glukagonu |
DE60136958D1 (de) | 2000-12-01 | 2009-01-22 | Takeda Pharmaceutical | Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz |
JP2002293799A (ja) * | 2001-03-29 | 2002-10-09 | Itoham Foods Inc | 新規ペプチド及びそれを含有する消化管運動抑制剤 |
ATE408414T1 (de) * | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | アルブミン融合タンパク質 |
WO2004071393A2 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
ES2737835T3 (es) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Bomba accionada hidráulicamente para la administración de medicamentos de larga duración |
US20080194483A1 (en) * | 2003-12-12 | 2008-08-14 | Brownlee Michael A | GLP-1 (9-36) methods and compositions |
EP1701731A4 (en) * | 2003-12-12 | 2009-08-05 | Einstein Coll Med | GLP-1 (9-36): METHODS AND COMPOSITIONS |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
ES2566058T3 (es) | 2006-03-30 | 2016-04-08 | Valeritas, Inc. | Dispositivo de suministro de fluidos de múltiples cartuchos |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
WO2010013012A2 (en) * | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
AU2009293019A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care Inc. | Solute concentration measurement device and related methods |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN101706297B (zh) * | 2009-08-10 | 2012-10-17 | 浙江鼎立实业有限公司 | 数显式微压和微流量综合检测台 |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
CN103566354B (zh) * | 2012-07-25 | 2017-12-05 | 江苏豪森药业集团有限公司 | 含有glp‑1类似物的衍生物或其可药用盐的药物组合物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AR094181A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
US20190218274A1 (en) * | 2016-05-06 | 2019-07-18 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
US4976959A (en) * | 1986-05-12 | 1990-12-11 | Burroughs Wellcome Co. | T-PA and SOD in limiting tissue damage |
US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5373016A (en) | 1993-05-28 | 1994-12-13 | Zeneca, Inc. | Protection of isothiazolinone biocides from free radicals |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
WO1998030231A1 (en) | 1997-01-07 | 1998-07-16 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
AU6586298A (en) * | 1997-03-31 | 1998-10-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
MY155270A (en) * | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
ES2347137T3 (es) | 2000-10-20 | 2010-10-26 | Amylin Pharmaceuticals, Inc. | Tratamiento de miocardio hibernante y cardiomiopatia diabetica con un peptido gpl-1. |
-
1999
- 1999-04-30 US US09/303,016 patent/US6429197B1/en not_active Ceased
-
2000
- 2000-05-01 DE DE60035987T patent/DE60035987T2/de not_active Expired - Lifetime
- 2000-05-01 MX MXPA01010937A patent/MXPA01010937A/es active IP Right Grant
- 2000-05-01 CN CN00806935A patent/CN1376072A/zh active Pending
- 2000-05-01 WO PCT/US2000/011652 patent/WO2000066142A2/en active Search and Examination
- 2000-05-01 CA CA2368772A patent/CA2368772C/en not_active Expired - Fee Related
- 2000-05-01 NZ NZ514609A patent/NZ514609A/xx not_active IP Right Cessation
- 2000-05-01 JP JP2000615026A patent/JP2002543145A/ja active Pending
- 2000-05-01 IL IL14582900A patent/IL145829A0/xx not_active IP Right Cessation
- 2000-05-01 AT AT00928616T patent/ATE369873T1/de not_active IP Right Cessation
- 2000-05-01 EP EP00928616A patent/EP1187628B1/en not_active Expired - Lifetime
- 2000-05-01 AU AU46825/00A patent/AU774084B2/en not_active Ceased
- 2000-05-01 ES ES00928616T patent/ES2290029T3/es not_active Expired - Lifetime
-
2001
- 2001-10-29 NO NO20015298A patent/NO20015298L/no not_active Application Discontinuation
-
2004
- 2004-08-06 US US10/913,309 patent/USRE41288E1/en not_active Expired - Lifetime
- 2004-09-15 AU AU2004212547A patent/AU2004212547B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CN1376072A (zh) | 2002-10-23 |
CA2368772C (en) | 2011-11-15 |
AU4682500A (en) | 2000-11-17 |
MXPA01010937A (es) | 2002-05-06 |
AU774084B2 (en) | 2004-06-17 |
AU2004212547B2 (en) | 2008-03-20 |
NO20015298L (no) | 2001-12-28 |
JP2002543145A (ja) | 2002-12-17 |
WO2000066142A3 (en) | 2002-01-24 |
WO2000066142A2 (en) | 2000-11-09 |
DE60035987D1 (de) | 2007-09-27 |
AU2004212547A1 (en) | 2004-10-14 |
ATE369873T1 (de) | 2007-09-15 |
CA2368772A1 (en) | 2000-11-09 |
NZ514609A (en) | 2004-03-26 |
IL145829A0 (en) | 2002-07-25 |
EP1187628B1 (en) | 2007-08-15 |
DE60035987T2 (de) | 2008-05-08 |
EP1187628A2 (en) | 2002-03-20 |
US6429197B1 (en) | 2002-08-06 |
ES2290029T3 (es) | 2008-02-16 |
USRE41288E1 (en) | 2010-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20015298L (no) | Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne | |
MXPA05006994A (es) | Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. | |
PT1173197E (pt) | Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido | |
CA2373266A1 (en) | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus | |
EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
CA2395165A1 (en) | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide | |
CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
AR032567A1 (es) | Propeptidos gdf modificados y estabilizados y usos de los mismos | |
EP1425031B8 (en) | Hdl for the treatment of stroke and other ischemic conditions | |
BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
EA200400658A1 (ru) | Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты) | |
MX2007009312A (es) | Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables. | |
HK1052139A1 (en) | Method and composition for the treatment of adenoviral ocular infections | |
EA200000141A1 (ru) | Способ лечения диабета тиазолидиндионом и сульфонилмочевиной | |
RU2003113987A (ru) | Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны | |
EA199901103A1 (ru) | Антивирусный препарат для инъекций | |
ECSP982542A (es) | Nuevo metodo de tratamiento iii | |
ECSP982534A (es) | Nuevo metodo de tratamiento | |
CO5150158A1 (es) | Tratamiento antidiabetico novedoso | |
RU2003138011A (ru) | Способ лечения хронического пиелонефрита | |
ECSP982541A (es) | Nuevo metodo de tratamiento ii | |
DE60306344D1 (de) | Behandlung von typ i diabetes mellitus mit wachstumshormonantagonisten | |
ECSP982591A (es) | Nuevo metodo de tratamiento iv | |
RU99116894A (ru) | Способ профилактики пролиферативной витреоретинопатии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |